BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Melaiu O, Lucarini V, Cifaldi L, Fruci D. Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors. Front Immunol 2019;10:3038. [PMID: 32038612 DOI: 10.3389/fimmu.2019.03038] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 32.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang W, Zhao Z, Li F. Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy. Molecular Immunology 2022;144:58-70. [DOI: 10.1016/j.molimm.2022.02.015] [Reference Citation Analysis]
2 Riggan L, Shah S, O'Sullivan TE. Arrested development: suppression of NK cell function in the tumor microenvironment. Clin Transl Immunology 2021;10:e1238. [PMID: 33456775 DOI: 10.1002/cti2.1238] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
3 Gregg RK. Implications of microgravity-induced cell signaling alterations upon cancer cell growth, invasiveness, metastatic potential, and control by host immunity. Int Rev Cell Mol Biol 2021;361:107-64. [PMID: 34074492 DOI: 10.1016/bs.ircmb.2021.01.004] [Reference Citation Analysis]
4 Cherif B, Triki H, Charfi S, Bouzidi L, Kridis WB, Khanfir A, Chaabane K, Sellami-Boudawara T, Rebai A. Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer. Sci Rep 2021;11:7550. [PMID: 33824367 DOI: 10.1038/s41598-021-87216-9] [Reference Citation Analysis]
5 Lim SA, Moon Y, Shin MH, Kim TJ, Chae S, Yee C, Hwang D, Park H, Lee KM. Hypoxia-Driven HIF-1α Activation Reprograms Pre-Activated NK Cells towards Highly Potent Effector Phenotypes via ERK/STAT3 Pathways. Cancers (Basel) 2021;13:1904. [PMID: 33920906 DOI: 10.3390/cancers13081904] [Reference Citation Analysis]
6 Grote S, Ureña-Bailén G, Chan KC, Baden C, Mezger M, Handgretinger R, Schleicher S. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment. Cells 2021;10:1020. [PMID: 33925968 DOI: 10.3390/cells10051020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Adv Cancer Res 2021;149:321-87. [PMID: 33579427 DOI: 10.1016/bs.acr.2020.10.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Coronado E, Yañez Y, Vidal E, Rubio L, Vera-Sempere F, Cañada-Martínez AJ, Panadero J, Cañete A, Ladenstein R, Castel V, Font de Mora J. Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets. Mol Oncol 2021;15:364-80. [PMID: 33252831 DOI: 10.1002/1878-0261.12868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Singh P, Yadav M, Niveria K, Verma AK. Nano-immunotherapeutics: targeting approach as strategic regulation at tumor microenvironment for cancer treatment. Exploration of Medicine. [DOI: 10.37349/emed.2022.00072] [Reference Citation Analysis]
10 Cocco C, Morandi F, Airoldi I. Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes. Cells 2021;10:927. [PMID: 33920505 DOI: 10.3390/cells10040927] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ayuso JM, Rehman S, Virumbrales-Munoz M, McMinn PH, Geiger P, Fitzgerald C, Heaster T, Skala MC, Beebe DJ. Microfluidic tumor-on-a-chip model to evaluate the role of tumor environmental stress on NK cell exhaustion. Sci Adv 2021;7:eabc2331. [PMID: 33597234 DOI: 10.1126/sciadv.abc2331] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
12 Li Y, Wu Y, Hu Y. Metabolites in the Tumor Microenvironment Reprogram Functions of Immune Effector Cells Through Epigenetic Modifications. Front Immunol 2021;12:641883. [PMID: 33927716 DOI: 10.3389/fimmu.2021.641883] [Reference Citation Analysis]
13 Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol 2021;14:73. [PMID: 33933160 DOI: 10.1186/s13045-021-01083-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Long S, Gu Y, An Y, Lin X, Chen X, Wang X, Liao C, Ouyang W, Wang N, He Z, Zhao X. Reovirus enhances cytotoxicity of natural killer cells against colorectal cancer via TLR3 pathway. J Transl Med 2021;19:185. [PMID: 33933132 DOI: 10.1186/s12967-021-02853-y] [Reference Citation Analysis]
15 Velichinskii RA, Streltsova MA, Kust SA, Sapozhnikov AM, Kovalenko EI. The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors. Int J Mol Sci 2021;22:11385. [PMID: 34768814 DOI: 10.3390/ijms222111385] [Reference Citation Analysis]
16 Matosevic S. Reprogramming of natural killer cells and their use in immunotherapies of solid tumors. Immunotherapy 2020;12:605-8. [PMID: 32418468 DOI: 10.2217/imt-2020-0051] [Reference Citation Analysis]
17 Wang Q, Liu J. Medulloblastoma: Immune microenvironment and targeted nano-therapy. OpenNano 2022;6:100035. [DOI: 10.1016/j.onano.2022.100035] [Reference Citation Analysis]
18 Brandetti E, Focaccetti C, Pezzolo A, Ognibene M, Folgiero V, Cotugno N, Benvenuto M, Palma P, Manzari V, Rossi P, Fruci D, Bei R, Cifaldi L. Enhancement of Neuroblastoma NK-Cell-Mediated Lysis through NF-kB p65 Subunit-Induced Expression of FAS and PVR, the Loss of Which Is Associated with Poor Patient Outcome. Cancers (Basel) 2021;13:4368. [PMID: 34503178 DOI: 10.3390/cancers13174368] [Reference Citation Analysis]
19 Tarannum M, Romee R. Cytokine-induced memory-like natural killer cells for cancer immunotherapy. Stem Cell Res Ther 2021;12:592. [PMID: 34863287 DOI: 10.1186/s13287-021-02655-5] [Reference Citation Analysis]
20 Zhang C, Liu Y. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy. Front Immunol 2020;11:1295. [PMID: 32714324 DOI: 10.3389/fimmu.2020.01295] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
21 Pan C, Wang Y, Liu Q, Hu Y, Fu J, Xie X, Zhang S, Xi M, Wen J. Phenotypic profiling and prognostic significance of immune infiltrates in esophageal squamous cell carcinoma. Oncoimmunology 2021;10:1883890. [PMID: 33628625 DOI: 10.1080/2162402X.2021.1883890] [Reference Citation Analysis]
22 Sportoletti P, De Falco F, Del Papa B, Baldoni S, Guarente V, Marra A, Dorillo E, Rompietti C, Adamo FM, Ruggeri L, Di Ianni M, Rosati E. NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. Int J Mol Sci 2021;22:6665. [PMID: 34206399 DOI: 10.3390/ijms22136665] [Reference Citation Analysis]
23 Tsuchiya H, Shiota G. Immune evasion by cancer stem cells. Regen Ther 2021;17:20-33. [PMID: 33778133 DOI: 10.1016/j.reth.2021.02.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Melaiu O, Chierici M, Lucarini V, Jurman G, Conti LA, De Vito R, Boldrini R, Cifaldi L, Castellano A, Furlanello C, Barnaba V, Locatelli F, Fruci D. Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma. Nat Commun 2020;11:5992. [PMID: 33239635 DOI: 10.1038/s41467-020-19781-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
25 Reusch U, Ellwanger K, Fucek I, Müller T, Schniegler-mattox U, Koch J, Tesar M. Cryopreservation of Natural Killer Cells Pre-Complexed with Innate Cell Engagers. Antibodies 2022;11:12. [DOI: 10.3390/antib11010012] [Reference Citation Analysis]
26 Shaver KA, Croom-Perez TJ, Copik AJ. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy. Front Immunol 2021;12:679117. [PMID: 33995422 DOI: 10.3389/fimmu.2021.679117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Fu R, Yu F, Wu W, Liu J, Li J, Guo F, Xu L, Wang F, Cui X. Bufalin enhances the killing efficacy of NK cells against hepatocellular carcinoma by inhibiting MICA shedding. Int Immunopharmacol 2021;101:108195. [PMID: 34678691 DOI: 10.1016/j.intimp.2021.108195] [Reference Citation Analysis]
28 Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol 2021;18:85-100. [PMID: 32934330 DOI: 10.1038/s41571-020-0426-7] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 28.5] [Reference Citation Analysis]
29 Gaggianesi M, Di Franco S, Pantina VD, Porcelli G, D'Accardo C, Verona F, Veschi V, Colarossi L, Faldetta N, Pistone G, Bongiorno MR, Todaro M, Stassi G. Messing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment. Front Oncol 2021;11:702642. [PMID: 34354950 DOI: 10.3389/fonc.2021.702642] [Reference Citation Analysis]
30 Domagala J, Lachota M, Klopotowska M, Graczyk-Jarzynka A, Domagala A, Zhylko A, Soroczynska K, Winiarska M. The Tumor Microenvironment-A Metabolic Obstacle to NK Cells' Activity. Cancers (Basel) 2020;12:E3542. [PMID: 33260925 DOI: 10.3390/cancers12123542] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Baker AE, Bahlmann LC, Xue C, Lu YH(, Chin AA, Cruickshank J, Cescon DW, Shoichet MS. Chemically and mechanically defined hyaluronan hydrogels emulate the extracellular matrix for unbiased in vivo and in vitro organoid formation and drug testing in cancer. Materials Today 2022. [DOI: 10.1016/j.mattod.2022.01.023] [Reference Citation Analysis]
32 Zang J, Zhang B, Wang Y, Wang X, Gou S. Design, synthesis and biological evaluation of antitumor platinum(II) agents conjugated with non-steroidal anti-inflammatory drug species. Bioorganic Chemistry 2022;120:105633. [DOI: 10.1016/j.bioorg.2022.105633] [Reference Citation Analysis]
33 Sanchez CE, Dowlati EP, Geiger AE, Chaudhry K, Tovar MA, Bollard CM, Cruz CRY. NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations. Transplant Cell Ther 2021;27:21-35. [PMID: 33007496 DOI: 10.1016/j.bbmt.2020.09.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Raskov H, Orhan A, Salanti A, Gaggar S, Gögenur I. Natural Killer Cells in Cancer and Cancer Immunotherapy. Cancer Lett 2021;520:233-42. [PMID: 34302920 DOI: 10.1016/j.canlet.2021.07.032] [Reference Citation Analysis]
35 Sordo-Bahamonde C, Lorenzo-Herrero S, Payer ÁR, Gonzalez S, López-Soto A. Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer. Int J Mol Sci 2020;21:E3726. [PMID: 32466293 DOI: 10.3390/ijms21103726] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
36 Lucarini V, Melaiu O, Tempora P, D'Amico S, Locatelli F, Fruci D. Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment. Cancers (Basel) 2021;13:433. [PMID: 33498755 DOI: 10.3390/cancers13030433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Mao J, Zheng Q, Jin L. Physiological Function of the Dynamic Oxygen Signaling Pathway at the Maternal-fetal Interface. Journal of Reproductive Immunology 2022. [DOI: 10.1016/j.jri.2022.103626] [Reference Citation Analysis]
38 Kronemberger GS, Miranda GASC, Tavares RSN, Montenegro B, Kopke ÚA, Baptista LS. Recapitulating Tumorigenesis in vitro: Opportunities and Challenges of 3D Bioprinting. Front Bioeng Biotechnol 2021;9:682498. [PMID: 34239860 DOI: 10.3389/fbioe.2021.682498] [Reference Citation Analysis]
39 Melo CM, Vidotto T, Chaves LP, Lautert-Dutra W, Reis RBD, Squire JA. The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer. Int J Mol Sci 2021;22:9550. [PMID: 34502458 DOI: 10.3390/ijms22179550] [Reference Citation Analysis]
40 Bödder J, Zahan T, van Slooten R, Schreibelt G, de Vries IJM, Flórez-Grau G. Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer. Front Immunol 2020;11:631713. [PMID: 33679726 DOI: 10.3389/fimmu.2020.631713] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
41 Chernosky NM, Tamagno I. The Role of the Innate Immune System in Cancer Dormancy and Relapse. Cancers (Basel) 2021;13:5621. [PMID: 34830776 DOI: 10.3390/cancers13225621] [Reference Citation Analysis]
42 Gaggero S, Witt K, Carlsten M, Mitra S. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy. Front Immunol 2020;11:621225. [PMID: 33584718 DOI: 10.3389/fimmu.2020.621225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
43 Ma SM, Dong J, Liang L, Liu XT, Meng XY, Zhang HS, Yang J. The prognostic and clinicopathological roles of microsatellite instability, PD-L1 expression and tumor-infiltrating leukocytes in familial adenomatous polyposis. Eur J Surg Oncol 2021:S0748-7983(21)00704-6. [PMID: 34483031 DOI: 10.1016/j.ejso.2021.08.032] [Reference Citation Analysis]
44 Melaiu O, Lucarini V, Giovannoni R, Fruci D, Gemignani F. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. Semin Cancer Biol 2020:S1044-579X(20)30156-5. [PMID: 32659257 DOI: 10.1016/j.semcancer.2020.07.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
45 Ebrahimiyan H, Tamimi A, Shokoohian B, Minaei N, Memarnejadian A, Hossein-Khannazer N, Hassan M, Vosough M. Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages. Int Immunopharmacol 2022;106:108587. [PMID: 35149294 DOI: 10.1016/j.intimp.2022.108587] [Reference Citation Analysis]
46 Russell É, Conroy MJ, Barr MP. Harnessing Natural Killer Cells in Non-Small Cell Lung Cancer. Cells 2022;11:605. [DOI: 10.3390/cells11040605] [Reference Citation Analysis]
47 Yang L, Li F, Cao Y, Liu Q, Jing G, Niu J, Sun F, Qian Y, Wang S, Li A. Multifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy. J Nanobiotechnology 2021;19:328. [PMID: 34663354 DOI: 10.1186/s12951-021-01073-2] [Reference Citation Analysis]
48 Kalavska K, Sestakova Z, Mlcakova A, Kozics K, Gronesova P, Hurbanova L, Miskovska V, Rejlekova K, Svetlovska D, Sycova-Mila Z, Obertova J, Palacka P, Mardiak J, Chovanec M, Chovanec M, Mego M. Are Changes in the Percentage of Specific Leukocyte Subpopulations Associated with Endogenous DNA Damage Levels in Testicular Cancer Patients? Int J Mol Sci 2021;22:8281. [PMID: 34361047 DOI: 10.3390/ijms22158281] [Reference Citation Analysis]
49 Radomska-Leśniewska DM, Białoszewska A, Kamiński P. Angiogenic Properties of NK Cells in Cancer and Other Angiogenesis-Dependent Diseases. Cells 2021;10:1621. [PMID: 34209508 DOI: 10.3390/cells10071621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Poggi A, Villa F, Fernadez JLC, Costa D, Zocchi MR, Benelli R. Three-Dimensional Culture Models to Study Innate Anti-Tumor Immune Response: Advantages and Disadvantages. Cancers (Basel) 2021;13:3417. [PMID: 34298630 DOI: 10.3390/cancers13143417] [Reference Citation Analysis]
51 Kim KS, Kim DH, Kim DH. Recent Advances to Augment NK Cell Cancer Immunotherapy Using Nanoparticles. Pharmaceutics 2021;13:525. [PMID: 33918941 DOI: 10.3390/pharmaceutics13040525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Mehdizadeh R, Shariatpanahi SP, Goliaei B, Peyvandi S, Rüegg C. Dormant Tumor Cell Vaccination: A Mathematical Model of Immunological Dormancy in Triple-Negative Breast Cancer. Cancers (Basel) 2021;13:E245. [PMID: 33440806 DOI: 10.3390/cancers13020245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Krug A, Martinez-Turtos A, Verhoeyen E. Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies. Cancers (Basel) 2021;14:183. [PMID: 35008348 DOI: 10.3390/cancers14010183] [Reference Citation Analysis]
54 Zhang L, Meng Y, Feng X, Han Z. CAR-NK cells for cancer immunotherapy: from bench to bedside. Biomark Res 2022;10:12. [PMID: 35303962 DOI: 10.1186/s40364-022-00364-6] [Reference Citation Analysis]
55 Eisinger S, Sarhan D, Boura VF, Ibarlucea-Benitez I, Tyystjärvi S, Oliynyk G, Arsenian-Henriksson M, Lane D, Wikström SL, Kiessling R, Virgilio T, Gonzalez SF, Kaczynska D, Kanatani S, Daskalaki E, Wheelock CE, Sedimbi S, Chambers BJ, Ravetch JV, Karlsson MCI. Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells. Proc Natl Acad Sci U S A 2020;117:32005-16. [PMID: 33229588 DOI: 10.1073/pnas.2015343117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
56 Vuletić A, Mirjačić Martinović K, Tišma Miletić N, Zoidakis J, Castellvi-Bel S, Čavić M. Cross-Talk Between Tumor Cells Undergoing Epithelial to Mesenchymal Transition and Natural Killer Cells in Tumor Microenvironment in Colorectal Cancer. Front Cell Dev Biol 2021;9:750022. [PMID: 34858978 DOI: 10.3389/fcell.2021.750022] [Reference Citation Analysis]
57 Pan S, Li T, Tan Y, Xu H. Selenium-containing nanoparticles synergistically enhance Pemetrexed&NK cell-based chemoimmunotherapy. Biomaterials 2022;280:121321. [PMID: 34922271 DOI: 10.1016/j.biomaterials.2021.121321] [Reference Citation Analysis]
58 Balta E, Wabnitz GH, Samstag Y. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors. Int J Mol Sci 2021;22:5736. [PMID: 34072260 DOI: 10.3390/ijms22115736] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Elahi R, Heidary AH, Hadiloo K, Esmaeilzadeh A. Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects. Stem Cell Rev Rep 2021. [PMID: 34472037 DOI: 10.1007/s12015-021-10246-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Gong J, Jin B, Shang L, Liu N. Characterization of the Immune Cell Infiltration Landscape of Thyroid Cancer for Improved Immunotherapy. Front Mol Biosci 2021;8:714053. [PMID: 34790698 DOI: 10.3389/fmolb.2021.714053] [Reference Citation Analysis]
61 Ouyang M, Yu C, Deng X, Zhang Y, Zhang X, Duan F. O-GlcNAcylation and Its Role in Cancer-Associated Inflammation. Front Immunol 2022;13:861559. [DOI: 10.3389/fimmu.2022.861559] [Reference Citation Analysis]
62 Kaweme NM, Zhou F. Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment. Front Immunol 2021;12:683381. [PMID: 34220833 DOI: 10.3389/fimmu.2021.683381] [Reference Citation Analysis]
63 Jafarzadeh L, Khakpoor-koosheh M, Mirzaei H, Mirzaei HR. Biomarkers for predicting the outcome of various cancer immunotherapies. Critical Reviews in Oncology/Hematology 2021;157:103161. [DOI: 10.1016/j.critrevonc.2020.103161] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
64 Ruppel KE, Fricke S, Köhl U, Schmiedel D. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy. Front Immunol 2022;13:822298. [DOI: 10.3389/fimmu.2022.822298] [Reference Citation Analysis]
65 Helms RS, Powell JD. Rethinking the adenosine-A2AR checkpoint: implications for enhancing anti-tumor immunotherapy. Curr Opin Pharmacol 2020;53:77-83. [PMID: 32781414 DOI: 10.1016/j.coph.2020.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Jin H, Kim HJ. NK Cells Lose Their Cytotoxicity Function against Cancer Stem Cell-Rich Radiotherapy-Resistant Breast Cancer Cell Populations. Int J Mol Sci 2021;22:9639. [PMID: 34502547 DOI: 10.3390/ijms22179639] [Reference Citation Analysis]
67 Abdolahi S, Ghazvinian Z, Muhammadnejad S, Ahmadvand M, Aghdaei HA, Ebrahimi-Barough S, Ai J, Zali MR, Verdi J, Baghaei K. Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model. Front Pharmacol 2021;12:733075. [PMID: 34588986 DOI: 10.3389/fphar.2021.733075] [Reference Citation Analysis]
68 Ansems M, Span PN. The tumor microenvironment and radiotherapy response; a central role for cancer-associated fibroblasts. Clin Transl Radiat Oncol 2020;22:90-7. [PMID: 32337377 DOI: 10.1016/j.ctro.2020.04.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
69 Peña-romero AC, Orenes-piñero E. Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers. Cancers 2022;14:1681. [DOI: 10.3390/cancers14071681] [Reference Citation Analysis]
70 Gallazzi M, Baci D, Mortara L, Bosi A, Buono G, Naselli A, Guarneri A, Dehò F, Capogrosso P, Albini A, Noonan DM, Bruno A. Prostate Cancer Peripheral Blood NK Cells Show Enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 Production and Secrete Monocyte-Recruiting and Polarizing Factors. Front Immunol 2020;11:586126. [PMID: 33569050 DOI: 10.3389/fimmu.2020.586126] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
71 Zhao H, Wong RJ, Stevenson DK. The Impact of Hypoxia in Early Pregnancy on Placental Cells. Int J Mol Sci 2021;22:9675. [PMID: 34575844 DOI: 10.3390/ijms22189675] [Reference Citation Analysis]
72 Marofi F, Al-Awad AS, Sulaiman Rahman H, Markov A, Abdelbasset WK, Ivanovna Enina Y, Mahmoodi M, Hassanzadeh A, Yazdanifar M, Stanley Chartrand M, Jarahian M. CAR-NK Cell: A New Paradigm in Tumor Immunotherapy. Front Oncol 2021;11:673276. [PMID: 34178661 DOI: 10.3389/fonc.2021.673276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Sivori S, Pende D, Quatrini L, Pietra G, Della Chiesa M, Vacca P, Tumino N, Moretta F, Mingari MC, Locatelli F, Moretta L. NK cells and ILCs in tumor immunotherapy. Mol Aspects Med 2021;80:100870. [PMID: 32800530 DOI: 10.1016/j.mam.2020.100870] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
74 Cui K, Hu S, Mei X, Cheng M. Innate Immune Cells in the Esophageal Tumor Microenvironment. Front Immunol 2021;12:654731. [PMID: 33995371 DOI: 10.3389/fimmu.2021.654731] [Reference Citation Analysis]
75 Wang G, Yang L, Hu M, Hu R, Wang Y, Chen B, Jiang X, Cui R. Comprehensive Analysis of the Prognostic Significance of Hsa-miR-100-5p and Its Related Gene Signature in Stomach Adenocarcinoma. Front Cell Dev Biol 2021;9:736274. [PMID: 34604236 DOI: 10.3389/fcell.2021.736274] [Reference Citation Analysis]
76 Bald T, Krummel MF, Smyth MJ, Barry KC. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat Immunol 2020;21:835-47. [PMID: 32690952 DOI: 10.1038/s41590-020-0728-z] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 23.0] [Reference Citation Analysis]
77 Han B, Song Y, Park J, Doh J. Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells. Journal of Controlled Release 2022. [DOI: 10.1016/j.jconrel.2022.01.049] [Reference Citation Analysis]
78 Navin I, Lam MT, Parihar R. Design and Implementation of NK Cell-Based Immunotherapy to Overcome the Solid Tumor Microenvironment. Cancers (Basel) 2020;12:E3871. [PMID: 33371456 DOI: 10.3390/cancers12123871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
79 Salemme V, Centonze G, Cavallo F, Defilippi P, Conti L. The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. Front Oncol 2021;11:610303. [PMID: 33777750 DOI: 10.3389/fonc.2021.610303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
80 Zinovkin DA, Lyzikova YA, Nadyrov EA, Petrenyov DR, Yuzugulen J, Pranjol MZI. Gamma-ray irradiation modulates PGRMC1 expression and the number of CD56+ and FoxP3+ cells in the tumor microenvironment of endometrial endometrioid adenocarcinoma. Radiat Oncol J 2021;39:324-33. [PMID: 34986554 DOI: 10.3857/roj.2021.00472] [Reference Citation Analysis]
81 Shen J, Liu T, Lv J, Xu S. Identification of an Immune-Related Prognostic Gene CLEC5A Based on Immune Microenvironment and Risk Modeling of Ovarian Cancer. Front Cell Dev Biol 2021;9:746932. [PMID: 34712666 DOI: 10.3389/fcell.2021.746932] [Reference Citation Analysis]
82 Kfoury Y, Baryawno N, Severe N, Mei S, Gustafsson K, Hirz T, Brouse T, Scadden EW, Igolkina AA, Kokkaliaris K, Choi BD, Barkas N, Randolph MA, Shin JH, Saylor PJ, Scadden DT, Sykes DB, Kharchenko PV; as part of the Boston Bone Metastases Consortium. Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. Cancer Cell 2021;39:1464-1478.e8. [PMID: 34719426 DOI: 10.1016/j.ccell.2021.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
83 Zanetti M, Xian S, Dosset M, Carter H. The Unfolded Protein Response at the Tumor-Immune Interface. Front Immunol 2022;13:823157. [DOI: 10.3389/fimmu.2022.823157] [Reference Citation Analysis]
84 Mylod E, Lysaght J, Conroy MJ. Natural killer cell therapy: A new frontier for obesity-associated cancer. Cancer Lett 2022;535:215620. [PMID: 35283210 DOI: 10.1016/j.canlet.2022.215620] [Reference Citation Analysis]
85 Morissette F, Mongeau-Pérusse V, Rizkallah E, Thébault P, Lepage S, Brissette S, Bruneau J, Dubreucq S, Stip E, Cailhier JF, Jutras-Aswad D. Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trial. Neuropsychopharmacology 2021. [PMID: 34331010 DOI: 10.1038/s41386-021-01098-z] [Reference Citation Analysis]
86 Kulemzin S, Evsyukov I, Belovezhets T, Taranin A, Gorchakov A. Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies. J Pers Med 2021;11:1182. [PMID: 34834534 DOI: 10.3390/jpm11111182] [Reference Citation Analysis]
87 Cho H, Ryu MH, Lee HE, Kim HD, Kang YK. Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab. Cancer Immunol Immunother 2021. [PMID: 34420059 DOI: 10.1007/s00262-021-03035-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Chen M, Li Y, Wu Y, Xie S, Ma J, Yue J, Lv R, Tian Z, Fang F, Xiao W. Anti-Tumor Activity of Expanded PBMC-Derived NK Cells by Feeder-Free Protocol in Ovarian Cancer. Cancers (Basel) 2021;13:5866. [PMID: 34831019 DOI: 10.3390/cancers13225866] [Reference Citation Analysis]
89 Paleari L, Pesce S, Rutigliani M, Greppi M, Obino V, Gorlero F, Vellone VG, Marcenaro E. New Insights into Endometrial Cancer. Cancers (Basel) 2021;13:1496. [PMID: 33804979 DOI: 10.3390/cancers13071496] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Alcantara M, Du Rusquec P, Romano E. Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors. Oncoimmunology 2020;9:1777064. [PMID: 32934880 DOI: 10.1080/2162402X.2020.1777064] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
91 Lu H, Zhao X, Li Z, Hu Y, Wang H. From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies. Front Oncol 2021;11:720501. [PMID: 34422667 DOI: 10.3389/fonc.2021.720501] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
92 Meng D, Pan H, He W, Jiang X, Liang Z, Zhang X, Xu X, Wang Z, Zheng J, Gong P, Li W, Cai L. In Situ Activated NK Cell as Bio‐Orthogonal Targeted Live‐Cell Nanocarrier Augmented Solid Tumor Immunotherapy. Adv Funct Materials. [DOI: 10.1002/adfm.202202603] [Reference Citation Analysis]
93 Phung SK, Miller JS, Felices M. Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy. Mol Diagn Ther 2021;25:577-92. [PMID: 34327614 DOI: 10.1007/s40291-021-00550-6] [Reference Citation Analysis]
94 Lee EHC, Wong DCP, Ding JL. NK Cells in a Tug-of-War With Cancer: The Roles of Transcription Factors and Cytoskeleton. Front Immunol 2021;12:734551. [PMID: 34594338 DOI: 10.3389/fimmu.2021.734551] [Reference Citation Analysis]